Investor Relations

Esperion Therapeutics, Inc. is an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers.

Esperion Therapeutics is a publicly traded company (since 2013) and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Esperion Therapeutics (NASDAQ: ESPR) 4:00 PM ET on Jun 30, 2015
Last Price Change Open Day High 52-Week High
3.48  up   (4.446%) 78.99 82.55 120.96
Volume Previous Close Day Low 52-Week Low
595,200 78.28 78.29 13.90

View all »   RSSRecent Releases

Jun 16, 2015
Esperion Therapeutics to Present at the JMP Securities Life Science Conference

Jun 15, 2015
Esperion Therapeutics Announces the Appointment of Scott Braunstein, M.D. to Board of Directors